Sale

Narcolepsy Drugs Market

Global Narcolepsy Drugs Market Share, Size, Research, Forecast: By Drug Class: Selective Histamine H3-Receptor Antagonist, Stimulants, Others; By Disease Type; By Dosage Form; By Route of Administration; By Population Type; By End User; By Treatment Channel; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Narcolepsy Drugs Market Outlook

The global narcolepsy drugs market reached a value of nearly USD 3.63 billion in 2023 and is further projected to achieve USD 8.85 billion by 2032, recording a CAGR of 10.4% over the forecast period of 2024-2032.

 

Narcolepsy Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The industry is being driven by the rapidly advancing technology, increased investment in the R&D sector by leading pharmaceutical companies, and the rising awareness regarding narcolepsy and its treatment among people.

 

Market Segmentation

Narcolepsy refers to a sleep disorder that causes excessive daytime drowsiness and is characterised by sleep paralysis and hallucinations, among other factors. It is a neurological disorder involving a reduced capacity to control sleep and wake cycles. The global narcolepsy drugs market can be segmented into disease type and therapeutic type.

 

Narcolepsy Drugs Market By Segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The industry can be divided based on its disease types into daytime extreme sleepiness and cataplexia, among others. The industry is broadly categorised based on its therapeutic types into:

  • Central Nervous System Stimulants
  • Tricyclic Antidepressants
  • Sodium Oxybate
  • Selective Serotonin Reuptake Inhibitor
  • Others

The EMR report looks into the regional narcolepsy drugs markets like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

 

Market Analysis

The increased prevalence of narcolepsy, awareness regarding sleep disorders due to narcolepsy awareness programmes and camps, and the growing presence of reimbursement policies are the major factors that are accelerating the growth of the global narcolepsy drugs market. Further, the rising disposable incomes and increased expenditure in the health care sector by the governments, particularly in the developing nations, is expected to aid the global narcolepsy drugs market over the forecast period. The adverse effects related to narcolepsy drugs, along with the chances of delayed diagnosis or misdiagnosis, are the major drawbacks, which may affect the industry growth in the forecast period.

 

Narcolepsy Drugs Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global narcolepsy drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Arena Pharmaceutical, Inc.
  • Jazz Pharmaceutical Plc
  • Bioprojet Pharma Sarl
  • Ligand Pharmaceuticals Incorporated
  • Shinogi Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Disease Type
  • Dosage Form
  • Route of Administration
  • Population Type
  • End User
  • Treatment Channel
  • Distribution Channel
  • Region
Breakup by Drug Class
  • Selective Histamine H3-Receptor Antagonist
  • Stimulants
  • Serotonin Reuptake Inhibitors (SSRIs)
  • Tricyclic Antidepressants
  • Central Nervous System Depressant
  • Others
Breakup by Disease Type
  • Narcolepsy with Cataplexy
  • Narcolepsy without Cataplexy
  • Secondary Narcolepsy
Breakup by Dosage Form
  • Tablet
  • Capsule
  • Injectables
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
Breakup by Population Type
  • Childrens
  • Adults
  • Geriatrics
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Avadell
  • Vallon Pharmaceuticals
  • Jazz Pharmaceuticals, Inc.
  • Jubilant Pharmova Limited
  • BIOPROJET
  • Hikma Pharmaceuticals PLC
  • Amneal Pharmaceuticals LLC
  • Teva Pharmaceutical Industries Ltd.
  • Ligand Pharmaceuticals Incorporated
  • Novartis AG
  • Mylan N.V.
  • Alkem Labs
  • Alembic Pharmaceuticals Limited
  • Torrent Pharmaceuticals Ltd.
  • Johnson & Johnson 
  • F. Hoffmann-La Roche Ltd.
  • Zydus Cadila
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Narcolepsy Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Narcolepsy Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Narcolepsy Epidemiology (2016-2031)
    5.3    Europe Narcolepsy Epidemiology (2016-2031)
    5.4    Asia-Pacific Narcolepsy Epidemiology (2016-2031)
    5.5    Latin America Narcolepsy Epidemiology (2016-2031)
    5.6    Middle East & Africa Narcolepsy Epidemiology (2016-2031)
6    Global Narcolepsy Drugs Market Overview 
    6.1    Global Narcolepsy Drugs Market Historical Value (2017-2023) 
    6.2    Global Narcolepsy Drugs Market Forecast Value (2024-2032)
7    Global Narcolepsy Drugs Market Landscape
    7.1    Global Narcolepsy Drugs: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Narcolepsy Drugs Product Landscape
        7.2.1    Analysis by Therapeutic Class
        7.2.2    Analysis by Diseases Type
        7.2.3    Analysis by Population Type
        7.2.4    Analysis by End User
8    Narcolepsy Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Narcolepsy Drugs Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Narcolepsy Drugs Market Segmentation
    11.1    Global Narcolepsy Drugs Market by Drug Class
        11.1.1    Market Overview
        11.1.2    Selective Histamine H3-Receptor Antagonist
        11.1.3    Stimulants
        11.1.4    Serotonin Reuptake Inhibitors (SSRIs)
        11.1.5    Tricyclic Antidepressants
        11.1.6    Central Nervous System Depressant
        11.1.7    Others
    11.2    Global Narcolepsy Drugs Market by Disease Type
        11.2.1    Market Overview
        11.2.2    Narcolepsy with Cataplexy
        11.2.3    Narcolepsy without Cataplexy
        11.2.4    Secondary Narcolepsy
    11.3    Global Narcolepsy Drugs Market by Dosage Form
        11.3.1    Market Overview
        11.3.2    Tablet
        11.3.3    Capsule
        11.3.4    Injectables
        11.3.5    Others
    11.4    Global Narcolepsy Drugs Market by Route of Administration
        11.4.1    Market Overview
        11.4.2    Oral
        11.4.3    Parenteral
    11.5    Global Narcolepsy Drugs Market by Population Type
        11.5.1    Market Overview
        11.5.2    Childrens
        11.5.3    Adults
        11.5.4    Geriatrics
    11.6    Global Narcolepsy Drugs Market by End User
        11.6.1    Market Overview
        11.6.2    Hospitals
        11.6.3    Specialty Clinics
        11.6.4    Homecare
        11.6.5    Others
    11.7    Global Narcolepsy Drugs Market by Treatment Channel
        11.7.1    Market Overview
        11.7.2    Public
        11.7.3    Private
    11.8    Global Narcolepsy Drugs Market by Distribution Channel
        11.8.1    Market Overview
        11.8.2    Hospital Pharmacy
        11.8.3    Online Pharmacy
        11.8.4    Retail Pharmacy
    11.9    Global Narcolepsy Drugs Market by Region
        11.9.1    Market Overview
        11.9.2    North America
        11.9.3    Europe 
        11.9.4    Asia Pacific
        11.9.5    Latin America
        11.9.6    Middle East and Africa
12    North America Narcolepsy Drugs Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Narcolepsy Drugs Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Narcolepsy Drugs Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Narcolepsy Drugs Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Narcolepsy Drugs Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Avadell
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Vallon Pharmaceuticals
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Jazz Pharmaceuticals, Inc.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Jubilant Pharmova Limited
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    BIOPROJET
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Hikma Pharmaceuticals PLC
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Amneal Pharmaceuticals LLC
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Teva Pharmaceutical Industries Ltd.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Ligand Pharmaceuticals Incorporated
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Novartis AG
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Mylan N.V.
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12     Alkem Labs
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    Alembic Pharmaceuticals Limited
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
    23.14     Torrent Pharmaceuticals Ltd.
        23.14.1    Financial Analysis
        23.14.2    Product Portfolio
        23.14.3    Demographic Reach and Achievements
        23.14.4    Mergers and Acquisitions
        23.14.5    Certifications
    23.15    Johnson & Johnson 
        23.15.1    Financial Analysis
        23.15.2    Product Portfolio
        23.15.3    Demographic Reach and Achievements
        23.15.4    Mergers and Acquisitions
        23.15.5    Certifications
    23.16    F. Hoffmann-La Roche Ltd.
        23.16.1    Financial Analysis
        23.16.2    Product Portfolio
        23.16.3    Demographic Reach and Achievements
        23.16.4    Mergers and Acquisitions
        23.16.5    Certifications
    23.17    Zydus Cadila
        23.17.1    Financial Analysis
        23.17.2    Product Portfolio
        23.17.3    Demographic Reach and Achievements
        23.17.4    Mergers and Acquisitions
        23.17.5    Certifications
24    Narcolepsy Drugs Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2020, the global narcolepsy drugs market attained a value of about USD 3.63 billion in 2023.

The market is projected to grow at a CAGR of 10.4% between 2024 and 2032.

The market is being driven by the rising awareness regarding narcolepsy and its treatment methods, technological advancements, and the increasing research and development (R&D) activities.

The market growth is anticipated to be defined by the rising disposable incomes, the increasing expenditure in the healthcare sector, and the introduction of favourable governmental initiatives to enhance the accessibility of narcolepsy drugs.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major disease types of narcolepsy drugs include daytime extreme sleepiness and cataplexia, among others.

The significant therapeutic types of narcolepsy drugs are central nervous system stimulants, tricyclic antidepressants, sodium oxybate, and selective serotonin reuptake inhibitor, among others.

The major players in the industry are Arena Pharmaceutical, Inc., Jazz Pharmaceutical Plc, Bioprojet Pharma Sarl, Ligand Pharmaceuticals Incorporated, Shinogi Inc., Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries Ltd., among others.

Analyst Review

The global narcolepsy drugs market attained a value of nearly USD 3.63 billion in 2023, driven by the rising awareness regarding narcolepsy. Aided by the introduction of various favourable governments initiatives, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 10.4%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on disease type, the narcolepsy drugs industry can be divided into daytime extreme sleepiness and cataplexia, among others. On the basis of therapeutic type, the market can be classified into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, and selective serotonin reuptake inhibitor, among others.  The major regional markets for narcolepsy drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Arena Pharmaceutical, Inc., Jazz Pharmaceutical Plc, Bioprojet Pharma Sarl, Ligand Pharmaceuticals Incorporated, Shinogi Inc., Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries Ltd., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER